
Developer of Intelligent Pelvic Floor Rehabilitation Diagnosis and Treatment System Products

丨Lilly's Tirzepatide Approved for Weight Loss Indication in China
Eli Lilly and Novo Nordisk have long been known as the "GLP-1 Duo," with the latter's "weight-loss wonder drug" semaglutide already approved for marketing in China. Now, with tirzepatide entering the weight-loss market in China, the two giants are set to face off head-to-head domestically.
According to Lilly, the newly approved GIP/GLP-1 receptor dual agonist tirzepatide (brand name: Mounjaro) will be used for long-term weight management in China. On May 21 this year, tirzepatide was approved in China for the indication of type 2 diabetes.
Although both semaglutide and tirzepatide belong to GLP-1 drugs, the difference is that semaglutide is a GLP-1 single-target drug, while tirzepatide is a GIP/GLP-1 dual-target drug.(Source of information:Shanghai Observer)
丨Beauty Farm Partners with Medlander to Advance Gynecological Anti-Aging

丨Haikou Longhua Zhongsheng Teng Beauty Shop Fined 10,000 for Tattooing Minors
7Month15On [date], Longhua Branch and Xiuying Branch of Haikou Market Supervision Administration successively issued administrative penalty cases.Among them, Haikou Longhua Zhongshengteng Beauty Shop was warned and fined.110,000 yuan.
Investigation results from the Longhua Branch of Haikou Market Supervision Administration indicated that on April 17, 2024, Haikou Longhua Zhongsheng Teng Beauty Salon, located at No. 22, West Gate, Longhua District, Haikou City, provided tattoo services to a minor named Wu某某 in its store. The tattoo was placed on the left wrist and featured the design "As Desired." Haikou Longhua Zhongsheng Teng Beauty Salon did not verify the minor's identity information before providing the tattoo service. The salon charged 100 yuan for the minor’s tattoo, with illegal earnings amounting to 100 yuan.
